Nurix Therapeutics (NRIX)
Develops protein-degradation medicines through DEL-AI and large-pharma collaborations.
$25.70
vs last close+0.29 (+1.14%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 113.36% | 117.65M shares | |
|---|---|---|---|
| 218 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.17% | 177.3K shares | |
| 4 holders · as of Sep 2, 2026 | |||
| Adds to | 113.53% | ||
103.78M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 113.53%; nothing is left for Other.
13F, as of Jun 30, 2026
218 holders · 117.65M shares · 49 new positions · 115 increased · 64 reduced · 30 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.77M | 8.45% | −155.3K | Aug 7, 2026 |
| Vestal Point Capital, LP | 8.05M | 7.76% | +1.55M | Aug 14, 2026 |
| Deep Track Capital, LP | 7.74M | 7.45% | +1.39M | Aug 14, 2026 |
| Rubric Capital Management LP | 7.23M | 6.96% | +4.75M | Aug 14, 2026 |
| FMR LLC | 5.49M | 5.29% | −56.1K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 5.44M | 5.24% | +2.15M | Aug 14, 2026 |
| Morgan Stanley | 4.76M | 4.59% | −169.5K | Aug 13, 2026 |
| State Street Corp | 4.68M | 4.51% | −464.0K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Redmile Group, LLC | 9.90% | 10.70M | 13G | Apr 24, 2026 |
| BlackRock, Inc. | 8.20% | 6.28M | 13G | Apr 23, 2025 |
| Baker Bros. Advisors LP | 7.20% | 7.53M | 13G | Feb 17, 2026 |
| Rubric Capital Management LP | 6.96% | 7.23M | 13G | Aug 14, 2026 |
| Vestal Point Capital, LP | 6.30% | 6.50M | 13G | May 15, 2026 |
| Deep Track Capital, LP | 6.17% | 6.35M | 13G | May 15, 2026 |
| FMR LLC | 5.40% | 5.54M | 13G | May 6, 2026 |
| T. Rowe Price Associates, Inc. | 5.30% | 5.44M | 13G | Aug 14, 2026 |
| Commodore Capital LP | 5.10% | 3.85M | 13G | Feb 14, 2025 |
| Vanguard Capital Management | 5.03% | 5.20M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 2, 2026 | Christine Ringofficer: Chief Legal Officer | Sale · 2 lots | 5,787 | $25.76 | 9,110 |
| Sep 1, 2026 | Gwenn Hansenofficer: Chief Scientific Officer | Sale | 1,452 | $25.47 | 117,227 |
| Aug 4, 2026 | Gwenn Hansenofficer: Chief Scientific Officer | Sale · 2 lots | 4,111 | $24.36 | 117,227 |
| Aug 5, 2026 | Gwenn Hansenofficer: Chief Scientific Officer | Sale | 4,356 | $25.00 | 117,227 |
| Aug 4, 2026 | Hans van Houteofficer: Chief Financial Officer | Sale · 2 lots | 4,761 | $24.36 | 40,166 |
| Aug 3, 2026 | Christine Ringofficer: Chief Legal Officer | Sale | 16,589 | $23.05 | 9,110 |
| Jul 30, 2026 | Gwenn Hansenofficer: Chief Scientific Officer | Sale | 3,847 | $23.38 | 121,338 |
| Jul 30, 2026 | Christine Ringofficer: Chief Legal Officer | Sale | 3,847 | $23.38 | 19,912 |
| Jul 30, 2026 | Hans van Houteofficer: Chief Financial Officer | Sale | 2,845 | $23.38 | 44,927 |
| Jul 2, 2026 | Christine Ringofficer: Chief Legal Officer | Sale | 11,008 | $23.56 | 13,579 |
House and Senate disclosures
Not reported.